A Cancer Detection Test Fails in Major Study
#Grail #Galleri test #cancer detection #clinical trial #blood test #early detection #Stage 3 cancer #Stage 4 cancer
📌 Key Takeaways
- Grail's Galleri cancer blood test failed to reduce late-stage cancers in a major British clinical trial
- The test has been sold in the US since 2021 and costs $949
- The study enrolled 142,000 healthy adults in Britain and followed them for three years
- Grail has applied for FDA approval and lobbied for Medicare coverage
- The results cast doubt on the effectiveness of multi-cancer early detection blood tests
📖 Full Retelling
Grail, a Silicon Valley-based company, announced on Thursday, February 20, 2026, that their closely watched cancer detection blood test failed to reduce late-stage cancers in a major clinical trial conducted in Britain. The test, known as Galleri, which looks for minuscule shards of cancer DNA in the blood to detect more than 50 types of cancer, was evaluated in a study involving 142,000 healthy adults aged 50 to 77 over three years. Despite high hopes and significant investment in this developing field of disease screening, the results cast doubt on the effectiveness of such blood tests for early cancer detection. The trial compared one group that received the Galleri test with another that didn't, and recipients did not show a significant reduction in cancers diagnosed at Stage 3 or Stage 4, though Grail executives noted a promising decrease in Stage 4 cancers. The test, which has been sold in the United States since 2021 at a cost of $949, was even featured in a Super Bowl advertisement this month, highlighting the high expectations surrounding this technology. Grail has sold nearly half a million tests to date and has been actively lobbying for Medicare coverage, which was recently authorized by Congress and signed into law by President Trump earlier this month, creating a potential pathway for government reimbursement. However, the failed trial could impact regulatory perspectives as Grail seeks FDA approval for the test, which is currently sold under a regulatory loophole without formal review.
🏷️ Themes
Medical Research, Cancer Detection, Clinical Trials, Healthcare Innovation
📚 Related People & Topics
Grail (company)
American health care company
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
Holy Grail
Treasure motif in Arthurian literature
The Holy Grail (French: Saint Graal, Breton: Graal Santel, Welsh: Greal Sanctaidd, Cornish: Gral) is a treasure that serves as an important motif in Arthurian literature. Various traditions describe the Holy Grail as a cup, dish, or stone with miraculous healing powers, sometimes providing eternal y...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
Advertisement SKIP ADVERTISEMENT Supported by SKIP ADVERTISEMENT Grail’s Cancer Detection Test Fails in Major Study A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in later stages of the disease. Listen to this article · 3:54 min Learn more Share full article 1 By Rebecca Robbins Feb. 20, 2026, 9:25 a.m. ET A blood test aimed at early detection of cancer failed to reduce late-stage cancers in a major clinical trial, the test’s maker, Grail, announced on Thursday . The results cast doubt on a developing field of screening for diseases that has generated enormous hopes and investment. The goal of the blood tests is to save and extend lives by detecting cancers when they can be more easily and successfully treated. Grail’s blood test was even briefly featured in a Super Bowl advertisement this month. Grail’s test, known as Galleri, looks for minuscule shards of cancer DNA in the blood and for more than 50 types of cancer, according to the company. It has been sold in the United States since 2021 and costs $949. Even though it is not yet approved by the Food and Drug Administration, the company sells it under a regulatory loophole that permits sales of certain tests without review. Very few insurers cover the test, so most people pay for it out of pocket. Grail has sold nearly half a million of the tests so far, including more than 185,000 last year. The company lobbied heavily for the U.S. government to cover the test under Medicare. The spending package passed by Congress and signed into law by President Trump earlier this month authorized Medicare to cover cancer detection tests, and Galleri could be among those that qualify to receive the government’s approval. Grail, which has its headquarters in Silicon Valley, announced the results of the study in a news release. The company plans to present more detailed results from the study at a cancer conference in the spring. Cancer researchers had been ...
Read full article at source